Zai Lab PT receives Investment Bank Analyst Rating Update
Zai Lab Limited (NASDAQ:ZLAB) reported Q2 EPS of ($1.44), $0.37 worse than the analyst estimate of ($1.07). Revenue for the quarter came in at $47.6 million versus the consensus...
Investing.com - Zai Lab (NASDAQ:ZLAB) reported on Tuesday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Zai Lab announced...
Peace talks boost market optimism China, Hong Kong benchmarks slip Dollar dips Key EventsOn Monday, US futures on the Dow Jones, S&P 500, NASDAQ, and Russell 2000 advanced with...
China is the world's second-largest economy behind the US. And as recent data from the World Bank highlights, China will help fuel a large part of the globe's economic...
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
|Average||107.94 (+183.69% Upside)|
|No. of Analysts||11|